PLUS1
30.52
-0.24 (-0.78%)
-0.24 (-0.78%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rafael Holdings Inc | RFL | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.24 | -0.78% | 30.52 | 16:00:59 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 30.59 | 29.80 | 31.9499 | 30.52 | 30.76 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,077 | 49,377 | $ 30.92 | $ 1,526,731 | 43,659 | 9.40 - 47.67 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:00:00 | 4,296 | $ 30.52 | USD |
Rafael Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 483.18M | 15.83M | 14.26M | $ 3.58M | $ - | -0.66 | -40.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 1.20% |
Rafael News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/24/2021 | 16:33 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) |
| 2/12/2021 | 15:24 | Edgar (US Regulatory) | Schedule 13g |
| 2/10/2021 | 09:00 | GlobeNewswire Inc. | LipoMedix Announces Manufacturing Agreement with ForDoz for.. |
| 2/08/2021 | 16:35 | Edgar (US Regulatory) | Withdrawal of Registration Statement (rw) |
| 1/28/2021 | 16:32 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/20/2021 | 16:31 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) |
| 1/19/2021 | 07:36 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RFL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 36.89 | 38.51 | 28.28 | 32.32 | 71,367 | -6.37 | -17.27% |
| 1 Month | 27.68 | 47.67 | 27.26 | 36.78 | 94,605 | 2.84 | 10.26% |
| 3 Months | 21.68 | 47.67 | 20.25 | 30.60 | 62,852 | 8.84 | 40.77% |
| 6 Months | 17.72 | 47.67 | 14.80 | 27.34 | 40,095 | 12.80 | 72.23% |
| 1 Year | 15.50 | 47.67 | 9.40 | 21.48 | 35,424 | 15.02 | 96.9% |
| 3 Years | 18.35 | 47.67 | 9.40 | 21.01 | 36,497 | 12.17 | 66.32% |
| 5 Years | 18.35 | 47.67 | 9.40 | 21.01 | 36,497 | 12.17 | 66.32% |
Rafael Description
| Rafael Holdings includes commercial real estate assets and interests in two clinical-stage pharmaceutical companies backed by a strong and liquid balance sheet. Rafael's real estate holdings are comprised by a 20-story commercial office building and associated parking garage in Newark, New Jersey, an office/data center building in Piscataway, New Jersey and an office condominium in Israel. Rafael's pharmaceutical holdings include interests in two clinical-stage oncology companies - Rafael Pharmaceuticals and LipoMedix. Rafael Pharmaceuticals is developing therapies that exploit the metabolic differences between normal cells and cancer cells in both solid and liquid cancers. LipoMedix is developing liposomal prodrugs designed to enhance the efficacy of certain chemotherapeutic therapies. |
